Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
Sydney, NSW-based Novotech operates in Biotechnology Research. It is privately held, and its site is novotech-cro.com. It holds 11 addresses on record across 11 office countries. Headcount on record is 2,092. Its work is tagged audits, medical writing and regulatory affairs. Four Australian registrations (ABN) are candidate matches. Its latest round on record is Private equity, with no amount recorded.
ABN37064856211
ABN33610783670
ABN59600809425
ABN26071874881
| NOVOTECH PTY. LTD. | ABN 37064856211 |
|---|---|
| NOVOTECH GROUP PTY. LTD. | ABN 33610783670 |
| NOVOTECH HOLDINGS PTY LIMITED | ABN 59600809425 |
| NOVOTECH (AUSTRALIA) PTY LTD | ABN 26071874881 |
| Confirmed matches | 0 of 4 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
| Countries | 11 |
|---|---|
| Primary country | AU |
All codes: AU CN HK IN KR MY NZ PH SG TH TW
| Rounds | 5 |
|---|---|
| Axis | 1997 to 2026 |
| Private equity · 1 May 2025 | not disclosed |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
Four Australian entities on the ABR: NOVOTECH PTY. LTD. (ABN 37 064 856 211), NOVOTECH GROUP PTY. LTD. (ABN 33 610 783 670), NOVOTECH HOLDINGS PTY LIMITED (ABN 59 600 809 425) and NOVOTECH (AUSTRALIA) PTY LTD (ABN 26 071 874 881). All low confidence.
2,092 counted staff profiles at January 2026, inside the self-reported 1,001–5,000 band.
11 addresses on record across 11 countries. Primary: Level 3, 235 Pyrmont Street, Pyrmont, Sydney, NSW 2009.
Five rounds. Latest 1 May 2025: private equity, no amount recorded.
16 tags on the brand's own list, among them audits, medical writing and regulatory affairs.
99 profiles list Novotech as a peer — 99th percentile in Biotechnology Research. It lists ten peers of its own.